1.050,00 excl. VAT

This is a full / one-time purchase. The full amount will be invoiced when completing the order.

Undiagnosed atrial fibrillation (VHF) increases the risk of stroke by a factor of 5.1 This risk can be reduced by early diagnosis and timely treatment.1 Innovative technologies such as C3+ can simplify and accelerate the diagnosis of VHF¹.

The C3+ records a high-quality 3-channel ECG signal, is lightweight, comfortable, reusable and has a battery life of 7 days.

The C3+ requires no cables, can be used with standard electrodes and offers both the physician and the patient a wireless Holter monitoring experience.

In addition, the C3+ integrates with two third-party analysis software programs that can be used either as stand-alone or cloud-based solutions.

¹ Kirchof P et al.: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893–2962